Tango Therapeutics (TNGX) Operating Income (2020 - 2025)
Historic Operating Income for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $14.1 million.
- Tango Therapeutics' Operating Income rose 14280.07% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.3 million, marking a year-over-year increase of 2101.89%. This contributed to the annual value of -$145.6 million for FY2024, which is 2752.14% down from last year.
- Per Tango Therapeutics' latest filing, its Operating Income stood at $14.1 million for Q3 2025, which was up 14280.07% from -$41.0 million recorded in Q2 2025.
- In the past 5 years, Tango Therapeutics' Operating Income registered a high of $14.1 million during Q3 2025, and its lowest value of -$42.5 million during Q1 2025.
- Moreover, its 5-year median value for Operating Income was -$29.6 million (2024), whereas its average is -$26.2 million.
- Its Operating Income has fluctuated over the past 5 years, first plummeted by 96515423.73% in 2021, then surged by 14280.07% in 2025.
- Quarter analysis of 5 years shows Tango Therapeutics' Operating Income stood at -$22.0 million in 2021, then crashed by 39.04% to -$30.6 million in 2022, then dropped by 14.55% to -$35.0 million in 2023, then decreased by 16.84% to -$40.9 million in 2024, then skyrocketed by 134.4% to $14.1 million in 2025.
- Its Operating Income was $14.1 million in Q3 2025, compared to -$41.0 million in Q2 2025 and -$42.5 million in Q1 2025.